Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Lantern Pharma Inc. has successfully completed patient enrollment in Japan for its Phase 2 HARMONIC(TM) trial targeting never-smoker non-small cell lung cancer patients, a significant step towards addressing a critical unmet medical need.
Lantern Pharma Inc. (NASDAQ: LTRN) has announced the completion of patient enrollment in Japan for its Phase 2 HARMONIC(TM) clinical trial, focusing on never-smoker non-small cell lung cancer (NSCLC) patients, ahead of schedule. This development is particularly noteworthy given the high incidence of never-smoker NSCLC in Japan, making it a strategic location for the trial. The investigational drug candidate, LP-300, is being tested in combination with standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy.
The trial's early completion in Japan, with 10 patients enrolled across five sites including the National Cancer Center in Tokyo, highlights Lantern Pharma's commitment to addressing the needs of underserved cancer markets. The company's AI-driven approach to drug development is poised to revolutionize the identification and acceleration of therapies for such specific patient groups. Additional trial data from Taiwan and the U.S. is anticipated in the third quarter of 2025, which could further validate the potential of LP-300 in treating never-smoker NSCLC.
For more information on Lantern Pharma's innovative approach to oncology drug development, visit https://ibn.fm/JXFqG. The company's progress in the HARMONIC(TM) trial represents a beacon of hope for never-smoker NSCLC patients, a demographic with historically limited treatment options.